Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

Rohini Sharma(Hammersmith Hospital), Hani Gabra(Royal Children's Hospital), Sarah P. Blagden(Churchill Hospital), Janet Graham(Beatson West of Scotland Cancer Centre)

BMC Cancer

July 11, 2011

10.1186/1471-2407-11-289

Cited by 10

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes

|Nature reviews. Cancer|2011|1.5k

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201